Halkier-Sørensen L, Laurberg G, Andresen J
J Am Acad Dermatol. 1987 May;16(5 Pt 1):999-1006. doi: 10.1016/s0190-9622(87)70129-7.
Ten children with disorders of keratinization (ichthyosis, 4, pityriasis rubra pilaris, 2, psoriasis, 2, and palmoplantar keratoderma, 2) were treated with etretinate for 0.5 to 9.6 years. The children ranged from 1.5 to 15.7 years of age. The total dose of etretinate ranged from 700 to 52,596 mg and the maintenance dose, from 0.21 to 0.86 mg/kg/day. Radiographic skeletal surveys were performed at various stages during treatment or following treatment. Bone abnormalities were found in eight children. Six children had periosteal thickening, two periosteal bone resorption, two osteoporosis, three disc narrowing, and one slender long bones. Compared with age- and sex-matched normal controls, the children had decreased cortical bone thickness of the second left metacarpal bone. The children's physical growth and laboratory investigations were normal. We recommend that children on long-term etretinate therapy be investigated regularly for bone changes.
10名患有角化异常疾病（鱼鳞病4例、毛发红糠疹2例、银屑病2例、掌跖角化病2例）的儿童接受了依曲替酯治疗，疗程为0.5至9.6年。这些儿童年龄在1.5至15.7岁之间。依曲替酯的总剂量为700至52596毫克，维持剂量为0.21至0.86毫克/千克/天。在治疗的不同阶段或治疗后进行了X线骨骼检查。在8名儿童中发现了骨骼异常。6名儿童有骨膜增厚，2名有骨膜骨质吸收，2名有骨质疏松，3名有椎间盘狭窄，1名有长骨纤细。与年龄和性别匹配的正常对照相比，这些儿童左第二掌骨的皮质骨厚度降低。这些儿童的身体生长和实验室检查均正常。我们建议对长期接受依曲替酯治疗的儿童定期进行骨骼变化检查。
